Liquid biopsy case study

A new option for oncologists and their patients


Lung cancer is the most common cancer worldwide, causing 1.59 million deaths each year; non-small cell lung cancer (NSCLC) comprises 85% of all lung cancers.


When it comes to treatment, confidence and trust are crucial—from the lab to the oncologist to the patient. The cobas® EGFR Mutation Test v2 was designed to foster that trust, by delivering clear and accurate results while enabling fast turnaround times and flexible workflows.

Watch the video below to learn more about the cobas® EGFR Mutation Test v2, including its new liquid biopsy option, and discover how both options fit seamlessly into your workflow.